

IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE

VOL 17 NO 2 JUN 2000

ISSN 0790-9667



'Oak (detail)' by Tom Molloy 1998-99 (pencil on paper, 25 x 32cm)
From the Collection at the Irish Museum of Modern Art, Royal Hospital Kilmainham, Dublin 8.

Editor-in Chief: Brian Lawlor

Editorial Co-ordinator: Anne
Henrichsen

Advertising Manager: Niamh
Gleeson

Founding Editor: Mark Hartman

Editors: Timothy Dinan (London)
David King (Belfast)

Deputy Editor: Brian O'Shea (Dublin)

Associate Editors: Ken Brown
(Belfast), Patricia Casey (Dublin)
Anthony Clare (Dublin), Stephen
Cooper (Belfast), Thomas Fahy
(Galway), Michael Fitzgerald (Dublin),
Brian Leonard (Galway), Roy
McClelland (Belfast), Aidan McGennis
(Dublin), Ciaran O Boyle (Dublin),
Eadbhard O Callaghan (Dublin), Art
O'Connor (Dublin), Ethna O Corman
(Belfast), Ian Pullen (Edinburgh), David
Sheehan (Tampara), Philip Shaith (Leeds)
Hugh Staughton (Dublin), John
Waddington (Dublin), Richard Williams
(Victoria)

Statistical Editor:
Roagna Conroy (Dublin)

Submissions & correspondence to:
The Editor,
Irish Journal of Psychological Medicine
25 Adelaide Street
Dun Laoghaire Co Dublin.

Telephone
01-2803967 Int +353-1-2803967

Fax
01-2807076 Int +353 1 2807076

Publisher
MedMedia Ltd
Medie House,
25 Adelaide Street
Dun Laoghaire, Co Dublin

Printing: New Cityview Press

Subscriptions
Rates per volume of four issues
(Mar, Jun, Sept, Dec)
STG£43 EU US\$96 USA, STG£53
elsewhere (single issues US\$28 USA
STG£13.25 elsewhere) incl. airmail
postage internationally.

**Subscription enquiries, orders,
and cheques made payable to:**
Royal Society of Medicine Press Ltd
1 Wimpole St
London W1M 8AE UK.
Tel: 0171 2902927
int: +44-171-2902927
Fax: 0171-2902929
int: +44-171-2902929

Circulation
3,000 to 54 countries.
The Journal participates in the World
Health Organisation project to improve
distribution of scientific materials on
mental health.
Publication does not imply
endorsement. Limited photocopying
authorisation granted for a fee to
Copyright Clearance Center
27 Congress Street, Salem, MA 01970,
USA, or to appropriate Reproduction
Rights Organisation; isolated non profit
academic photocopying excepted

EDITORIAL

- 41 Is neuroticism a modifiable risk factor for depression?
Niall Gormley

ORIGINAL PAPERS

- 43 The pattern of support networks among the community dwelling elderly in urban Ireland: variations with mental disorder
Michael Kirby, Aisling Denihan, Irene Bruce, Davis Coakley, Brian A Lawlor
- 50 Attitudes to doctors and medicine: a failure to replicate
Ronan Conroy, Ruwani Siriwardena, Olive Smyth, Hannah M McGee Paula Fernandes
- 54 Teenagers in adult psychiatric inpatient care in Northern Ireland
Sinéad McGilloway, Michael Donnelly, David Scott

BRIEF REPORT

- 59 Suicide rates in Irish counties
John F Connelly David Lester

REVIEW

- 62 Good practice in ADHD
Eiona McNicholas

HISTORICAL

- 67 Doctor Maurice O Connor Drury, Wittgenstein's pupil
John Wallace

CASE REPORTS

- 69 A case of co-existent Capgras and deClerambault's syndrome with a history of morbid jealousy
Noel Kennedy, Brendan Kelly David Shantey, Michael Gill
- 71 Sleep paralysis and attempted suicide: a case report
Gary Hosty, Joanna Abbott

- 46a John Dunne Medal
- 58 Guidelines for authors
- 73 Letters to the Editor
- 78 Book Reviews


Indexed and abstracted by BIOLOGICAL ABSTRACTS (BIOSIS Previews); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE/INIST. PASCAL; EXCERPTA MEDICA/EMBASE; INSTITUTE FOR SCIENTIFIC INFORMATION: CURRENT CONTENTS/Social & Behavioural Sciences (Social Science CITATION INDEX, Research Alert); PSYCHOLOGICAL ABSTRACTS (PsycINFO/PsycLIT); Cumulative Index to Nursing & Allied Health Literature, Current AIDS Literature (CAB Abstracts), International Pharmaceutical Abstracts, Linguistics & Language Behaviour Abstracts, Nutrition Abstracts and Reviews, (CAB Abstracts), Referativnyi Zhurnal, Social Planning/Policy & Development Abstracts, Social Work Research & Abstracts, Sociological Abstracts.

Microfilm, microfiche & article copies from University Microfilms International, 300 North Zeeb Rd., Ann Arbor, MI 48106, USA. Journal included in the Adonis service, whereby article copies can be printed out from compact disks (CD-ROM) on demand; explanatory leaflet available from ADONIS BV, PO Box 639, 1000 AV Amsterdam, The Netherlands. Journal listed in Ulrich's International Periodicals Directory (Bowker International Serials Database), EBSCO's Selected Periodicals for the Medical and Health Sciences, & EBSCO's Librarians' Handbook.



Fast Response

Can start to improve symptoms of depression within 7 days¹



LUSTRAL™ 50mg

sertraline

A first choice antidepressant



Abbreviated Prescribing Information:
LUSTRAL™ (sertraline)

Presentation: Tablets containing 50mg or 100mg sertraline. **Indications:** Treatment of symptoms of depressive illness, including accompanying symptoms of anxiety. Prevention of relapse or recurrence of depressive episodes, including accompanying symptoms of anxiety. Obsessive compulsive disorder (OCD). Panic disorder, with or without agoraphobia.

Dosage: Lustral should be given as a single daily dose. The initial dose in depression and OCD is 50mg and the usual antidepressant dose is 50mg. The initial dose in panic disorder is 25mg, increasing to 50mg after one week. Dosage can be further increased, if appropriate, to a maximum of 200mg daily. Patients should be maintained on the lowest effective dose. **Use in children:** Not recommended. **Use in the elderly:** Usual adult dose. **Contraindications:** Hypersensitivity to this group of drugs. Hepatic insufficiency, unstable epilepsy and convulsant disorders, pregnancy and lactation. Do not use with, or within two weeks of ending treatment with, MAOIs. At least 14 days should elapse before

starting any MAOI following discontinuation of Lustral. **Precautions, warnings:** Renal insufficiency, ECT, epilepsy, driving. Lustral should be discontinued in a patient who develops seizures. Lustral should not be administered with benzodiazepines or other tranquilizers in patients who drive or operate machinery. Serotonergic drugs such as tryptophan or fenfluramine should be used with caution. The patient should be monitored for signs of suicide or mania. **Drug Interactions:** Caution with other centrally active medication. Lithium levels should be monitored. Although Lustral has been shown to have no adverse interaction with alcohol, concomitant use with alcohol is not recommended. The potential for Lustral to interact with other highly protein bound drugs should be borne in mind. Interactions with e.g. warfarin, diazepam, tolbutamide and cimetidine have not been fully assessed. With warfarin prothrombin time should be monitored when Lustral is initiated or stopped. **Side-Effects:** Dry mouth, nausea, diarrhoea/loose stools, ejaculatory delay, tremor, increased sweating, dizziness, insomnia, somnolence, headache, anorexia and dyspepsia. Rarely, abnormal LFTs, hyponatraemia. The following have been reported with Lustral but may have no causal relationship: vomiting, abdominal pain, movement disorders,

convulsions, menstrual irregularities, hyperprolactinaemia, galactorrhoea, rash and alopecia. Rarely, pancreatitis, serious liver events, altered platelet function, abnormal bleeding and purpura. As with other serotonin re-uptake inhibitors rare reports of agitation, confusion, depersonalisation, hallucinations, nervousness, postural hypotension, hypo/hypertension, tachycardia and arrhythmias. Withdrawal reactions have been reported with Lustral. Common symptoms include dizziness, paraesthesia, headache, anxiety and nausea. Abrupt discontinuation of treatment with Lustral should be avoided. The majority of symptoms experienced on withdrawal of Lustral are non-serious and self-limiting. **Legal Category:** S1A. **Package Quantities:** 50mg tablet (PA 822/1/4) Calendar pack of 28; 100mg tablet (PA 822/1/5) Calendar pack of 28. **Product Authorisation Holder:** Pfizer (Ireland) Limited, Parkway House, Ballymount Road Lower, Dublin 12, Republic of Ireland. Further information on request: Pfizer (Ireland) Limited. Date last revised: June 1999. **Reference:** 1. Lapiere YD. *Int Clin Psychopharmacol* 1991; 6 (Suppl. 2): 23-35.



67577 November 99